| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
Melanin synthesis and TYR activity are both markedly suppressed by bevacichin. In A375 cells, bevacichin (10 µM) suppresses the expression of TYR and JNK proteins as well as TYR, TRP-1, TRP-2, ERK1, ERK2, and JNK2 mRNA. Following psoralen dihydroflavone treatment, ICI182780 and U0126 cAN substantially reduced the protein expression levels and mRNA expression of TYR, TRP-1, TRP-2, ERK1, ERK2, and JNK2 [1]. In ORO staining tests, bevacicol accumulates lipids in a dose-dependent manner. When compared to control cells, Bavachin at 10 µM dramatically boosted preadipocyte proliferation in the MTT experiment. Moreover, during preadipocyte proliferation, bevacichin can enhance BrdU's binding to freshly produced DNA. Insulin improved BrdU incorporation; this effect was further amplified when insulin and tonic hydroflavone were administered together at 2 µM and 10 µM. In differentiated adipocytes, bevacichin stimulates PPARγ transcriptional activity and activates adipogenic factors. Bavachin increases the absorption of glucose induced by insulin by means of the GLUT4 translocation of the AMPK and Akt pathways [2]. The activities of hMAO-A and hMAO-B are considerably increased by BVN [3]. In recombinant ER, bavacin competitively displaces [3H]E2 to demonstrate ER ligand-binding activity. Using ERα or ERβ and estrogen-responsive luciferase plasmids, the estrogenic activity of Bavachin was assessed in CV-1 cells by a transient transfection technique; the EC50 values were 320 nM and 680 nM, respectively. Bavachin increases the mRNA levels of estrogen-responsive genes (such as pS2 and PR) and decreases the protein level of ERα through the proteasome pathway [4].
|
|---|---|
| References |
|
| Additional Infomation |
Bavachin has been reported in Lespedeza floribunda, Lespedeza cyrtobotrya, and other organisms with data available.
|
| Molecular Formula |
C₂₀H₂₀O₄
|
|---|---|
| Molecular Weight |
324.37
|
| Exact Mass |
324.136
|
| CAS # |
19879-32-4
|
| PubChem CID |
14236566
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
558.3±50.0 °C at 760 mmHg
|
| Flash Point |
202.1±23.6 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.622
|
| LogP |
4.85
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
24
|
| Complexity |
474
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC(=CCC1=CC2=C(C=C1O)O[C@@H](CC2=O)C3=CC=C(C=C3)O)C
|
| InChi Key |
OAUREGNZECGNQS-IBGZPJMESA-N
|
| InChi Code |
InChI=1S/C20H20O4/c1-12(2)3-4-14-9-16-18(23)11-19(24-20(16)10-17(14)22)13-5-7-15(21)8-6-13/h3,5-10,19,21-22H,4,11H2,1-2H3/t19-/m0/s1
|
| Chemical Name |
(2S)-2,3-dihydro-7-hydroxy-2-(4-hydroxyphenyl)-6-(3-methyl-2-butenyl)-4H-1-benzopyran-4-one
|
| Synonyms |
CorylifolinBavachin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~308.29 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.41 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.41 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.41 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0829 mL | 15.4145 mL | 30.8290 mL | |
| 5 mM | 0.6166 mL | 3.0829 mL | 6.1658 mL | |
| 10 mM | 0.3083 mL | 1.5414 mL | 3.0829 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
